Biocon to launch diabetes, weight-loss drug in emerging markets
Biocon, a Bengaluru-based pharma company, is gearing up to launch its generic version of semaglutide—a popular diabetes and weight-loss drug—in Canada, India, and other emerging markets.
With the patent expiring in early 2026, Biocon has already finished development and is filing for approvals in several markets, with filings underway or imminent in Canada and other regions.
If all goes well, their version could hit shelves by early 2027.
Making a difference in people's lives
Semaglutide is in high demand but can be expensive. Biocon's move could make it much more affordable and accessible for people who need it most.
CEO Siddharth Mittal shared that they're likely to be among the first with a generic option: "We expect approvals by late 2026."
The company's strong track record with similar drugs suggests they know how to get things done—good news for anyone watching the future of healthcare costs.